Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study Of Active Immunotherapy With Autologous Dendritic Cells Infected With CEA-6D Expressing Fowlpox -Tricom In Patients With Advanced Or Metastatic Malignancies Expressing CEA

NCT00027534 is registered in ClinicalTrials.gov with Michael Morse, MD as lead sponsor.

NCT NCT00027534
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00027534 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study Of Active Immunotherapy With Autologous Dendritic Cells Infected With CEA-6D Expressing Fowlpox -Tricom In Patients With Advanced Or Metastatic Malignancies Expressing CEA
Lead sponsor
Michael Morse, MD
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2002
Completion date
October 31, 2007
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, colorectal cancer, gallbladder cancer, gastric cancer, head and neck cancer, liver cancer, ovarian cancer, pancreatic cancer, testicular germ cell tumor